This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Prometheus Biosciences Beheer

Beheer criteriumcontroles 1/4

Prometheus Biosciences' CEO is Mark McKenna, appointed in Sep 2019, he has a tenure of 3.75 years. His total yearly compensation is $19.94M , comprised of 3% salary and 97% bonuses, including company stock and options. He directly owns 0.29% of the company’s shares, worth $28.17M. The average tenure of the management team and the board of directors is 2.5 years and 2.3 years respectively.

Belangrijke informatie

Mark McKenna

Algemeen directeur

US$19.9m

Totale compensatie

Percentage CEO-salaris	3.0%
Dienstverband CEO	3.8yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	2.3yrs

Recente managementupdates

Recent updates

We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth

May 17

Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

Dec 03

We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

Aug 19

Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M

Aug 11

We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

May 04

Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases

Dec 08

Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Nov 16

Prometheus Biosciences: Precision Medicine For IBD

Sep 22

Analyse CEO-vergoeding

Hoe is Mark McKenna's beloning veranderd ten opzichte van Prometheus Biosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-US$151m
Dec 31 2022	US$20m	US$592k	-US$142m
Sep 30 2022	n/a	n/a	-US$133m
Jun 30 2022	n/a	n/a	-US$123m
Mar 31 2022	n/a	n/a	-US$108m
Dec 31 2021	US$12m	US$566k	-US$90m
Sep 30 2021	n/a	n/a	-US$69m
Jun 30 2021	n/a	n/a	-US$50m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$3m	US$500k	-US$31m
Dec 31 2019	US$976k	US$157k	-US$17m

Compensatie versus markt: Mark's total compensation ($USD19.94M) is above average for companies of similar size in the US market ($USD8.17M).

Compensatie versus inkomsten: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark McKenna (43 yo)

3.8yrs

Tenure

US$19,936,088

Compensatie

Mr. Mark C. Mckenna serves as President, Chief Executive Officer, Chairman of the Board at Prometheus Biosciences, Inc. since August 2021. He serves as Director of Rebalance Health, Inc. He serves as Execu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark McKenna	President	3.8yrs	US$19.94m	0.29% $ 28.2m
Keith Marshall	Chief Financial Officer	2.8yrs	US$7.12m	0.18% $ 17.6m
Mark Stenhouse	Chief Operating Officer	2.3yrs	US$6.16m	0.035% $ 3.4m
Olivier Laurent	Chief Scientific Officer & Head of R&D	1.5yrs	geen gegevens	geen gegevens
Noel Kurdi	Vice President of Investor Relations & Communications	no data	geen gegevens	geen gegevens
Timothy Andrews	General Counsel & Secretary	2.6yrs	geen gegevens	geen gegevens
Nori Ebersole	Chief People Officer	2.2yrs	geen gegevens	geen gegevens
Allison Luo	Chief Medical Officer	4.8yrs	US$4.24m	0% $ 0
Thierry Dervieux	Chief Development Officer of Diagnostics & Medical Laboratory Director	3.5yrs	geen gegevens	geen gegevens
Chris Doughty	Chief Business Officer	2.4yrs	geen gegevens	geen gegevens
Evan McClure	Chief of Staff & VP of Business Operations	2.4yrs	geen gegevens	geen gegevens
Vika Brough	Senior Vice President of Finance	no data	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: RXDX's management team is considered experienced (2.5 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark McKenna	President	3.8yrs	US$19.94m	0.29% $ 28.2m
Fred Hassan	Independent Director	2.1yrs	US$441.91k	0% $ 0
Joseph Papa	Lead Independent Director	2.8yrs	US$463.28k	0.031% $ 3.0m
Mary Szela	Independent Director	2.3yrs	US$442.29k	0% $ 0
Judith Swain	Independent Director	2.3yrs	US$429.79k	0% $ 0
Helen Adams	Independent Director	2.3yrs	US$444.04k	0.0010% $ 100.4k
Bruce Sands	Chairman of Scientific Advisory Board	1.1yrs	geen gegevens	geen gegevens
Stephan Targan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Martin Hendrix	Independent Director	2.7yrs	US$439.79k	0% $ 0
James Laur	Director	3.2yrs	US$424.79k	0% $ 0
Dermot McGovern	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Donna Griebel	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: RXDX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

This company has been acquired

Prometheus Biosciences Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Chief Financial Officer exercised options to buy US$16m worth of stock.

President notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$1.2m worth of stock

Chief Financial Officer exercised options and sold US$578k worth of stock

President notifies of intention to sell stock

High number of new and inexperienced directors

Recent updates

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Prometheus Biosciences, Inc. (NasdaqGS:RXDX) from a group of shareholders.

Chief Financial Officer exercised options to buy US$16m worth of stock.

Consensus revenue estimates decrease by 12%

We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth

Consensus revenue estimates decrease by 34%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.6% to US$163

President notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$1.2m worth of stock

Consensus revenue estimates fall by 66%

Full year 2022 earnings released: US$3.49 loss per share (vs US$2.88 loss in FY 2021)

Chief Financial Officer exercised options and sold US$578k worth of stock

President notifies of intention to sell stock

Prometheus Biosciences Reports Positive Data on Two of Its Clinical Trials

Prometheus Biosciences Announces Positive Results for Pra023 in Both Artemis-UC Phase 2 and Apollo-Cd Phase 2A Studies Enabling Pathway to Both First-In-Class and Best-In-Class Anti-Tl1a Mab

Price target increased to US$78.45

Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.90 loss per share (vs US$0.70 loss in 3Q 2021)

Chief Medical Officer notifies of intention to sell stock

Prometheus Biosciences, Inc. Receives FDA Clearance of IND Application for Its Second Precision Program, PRA052

Price target increased to US$61.91

We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully

Consensus revenue estimates increase by 32%

Price target increased to US$57.73

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M

Prometheus Biosciences, Inc. Unveils Its Corresponding Clinical Candidate, PRA052, an Anti-CD30L Monoclonal Antibody

Chief Medical Officer notifies of intention to sell stock

Prometheus Biosciences, Inc. Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis

Prometheus Biosciences, Inc.(NasdaqGS:RXDX) dropped from Russell 2500 Value Index

Consensus forecasts updated

Prometheus Biosciences Provides Enrollment Update in Apollo-Cd and Artemis-Uc Global Phase 2 Studies

Consensus forecasts updated

Prometheus Biosciences, Inc. Appoints Marla Hochfeld as Senior Vice President of Clinical Development and Clinical Affairs

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely

High number of new and inexperienced directors

Chairman of Scientific Advisory Board notifies of intention to sell stock

Prometheus Biosciences, Inc., Annual General Meeting, May 19, 2022

Prometheus Biosciences, Inc. Initiates Third Phase 2 Study of Pra023 for Systemic Sclerosis-Associated Interstitial Lung Disease

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Medical Officer notifies of intention to sell stock

Chairman of Scientific Advisory Board notifies of intention to sell stock

Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases

Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans

Third quarter 2021 earnings released: US$0.70 loss per share

Prometheus Biosciences: Precision Medicine For IBD

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Prometheus Biosciences, Inc. Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-To-Severe Crohn’s Disease

Prometheus Biosciences, Inc. Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-To-Severe Ulcerative Colitis

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd